R&D platform for target gene screening and engineered strain construction

Using this platform, we screen for target genes and construct engineered strains that efficiently express the desired proteins or naked plasmids suitable for gene therapy. Currently, all of the company’s projects are developed based on this platform.

R&D platform for biotechnology drug process scale-up and large-scale production

Through this platform, process scale-up and large-scale production of the projects are being carried out. Currently, the NL002 and NL003 projects have completed process scale-up and have reached production scale.

Microbial Expression Platform for the Development of Recombinant Protein Therapeutics

Recombinant protein-based drugs that do not require post-translational modifications, such as projects NL002 and NL005, have been developed through this platform.

Ophthalmic Drug Open Platform

An integrated blow-fill-seal platform for ophthalmic drop production has been established. Through this platform, ophthalmic drops can be developed and manufactured.

Naked Plasmid Gene Therapy Drug Development Platform

Develop gene therapy drugs using naked plasmids as vectors through this platform, such as the NL003 project.

R&D Platform for Recombinant Protein Drug Expression in Mammalian Cells

Recombinant protein-based drugs requiring post-translational modifications, such as NL201 and NL202, have been developed through this platform.